US Patent Issued to HANMI PHARM. on Nov. 3 for "Pharmaceutical composition for preventing or treating bone diseases, comprising triple agonist or conjugate thereof having activity with respect to all of glucagon, GLP-1 and GLP receptors" (South Korean Inventors)

ALEXANDRIA, Va., Nov. 3 -- United States Patent no. 12,779,018, issued on Nov. 3, was assigned to HANMI PHARM. Co. LTD. (Hwaseong-si, South Korea).

"Pharmaceutical composition for preventing or treating bone diseases, comprising triple agonist or conjugate thereof having activity with respect to all of glucagon, GLP-1 and GLP receptors" was invented by Jong Suk Lee (Hwaseong-si, South Korea), Sang Don Lee (Hwaseong-si, South Korea) and Sang Hyun Lee (Hwaseong-si, South Korea).

According to the abstract* released by the U.S. Patent & Trademark Office: "A therapeutic use of a triple agonist and/or a long-acting conjugate thereof having activity with respect to all of glucagon, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotr...